January 29, 2016

Contact:
Corporate Communications,
Astellas Pharma Inc.
TEL +81-3-3244-3201

Financial Results of Astellas for the First Nine Months of FY2015

Japan, January 29, 2016 – Astellas Pharma Inc. (hereinafter referred to as "the Company") today announced the financial results for the first nine months of the fiscal year 2015 (FY2015) ending March 31, 2016.

Consolidated financial results for the first nine months of FY2015 (April 1, 2015 – December 31, 2015) (core basis)

(Millions of yen)

	First nine months of FY2014	**First nine months of FY2015**	Change (%)
Sales	952,772	**1,065,666**	+112,894 (+11.8%)
Core operating profit	200,193	**233,863**	+33,670 (+16.8%)
Core profit for the period	140,285	**169,379**	+29,094 (+20.7%)
Basic core earnings per share (yen)	63.42	**78.16**	+14.75 (+23.3%)

Cautionary statement regarding forward-looking information

This press release includes forward-looking statements based on a number of assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties. Consequently, any statements herein do not constitute assurances regarding actual results by the Company. Actual financial results may differ materially depending on a number of factors, including adverse economic conditions, currency exchange rate fluctuations, adverse legislative and regulatory developments, delays in new product launches, the pricing and product initiatives of competitors, the inability of the Company to market existing and new products effectively, interruptions in production, infringements of the Company's intellectual property rights and the adverse outcome of material litigation.

1. Qualitative information on consolidated financial results for the first nine months of FY2015

(1) Information on business performance

[Consolidated financial results (core basis (Note))]

Consolidated financial results (core basis) in the first nine months of FY2015 showed increases in sales, core operating profit and core profit for the period, as follows.

Consolidated financial results (core basis)

(Millions of yen)

	First nine months of FY2014	**First nine months of FY2015**	Change (%)
Sales	952,772	**1,065,666**	+112,894 (+11.8%)
Core operating profit	200,193	**233,863**	+33,670 (+16.8%)
Core profit for the period	140,285	**169,379**	+29,094 (+20.7%)
Basic core earnings per share (yen)	63.42	**78.16**	+14.75 (+23.3%)

Research and development (R&D) expenses

(Millions of yen)

	First nine months of FY2014	**First nine months of FY2015**	Change
R&D expenses	148,000	**164,996**	+16,996

(Note) The Company discloses financial results on a core basis as an indicator of its recurring profitability. Certain items reported in financial results on a full basis that are deemed to be non-recurring items by the Company are excluded as non-core items from these financial results on a core basis. These adjusted items include impairment losses, gain/loss on sales of property, plant and equipment, restructuring costs, loss on disaster, a large amount of losses on compensation or settlement of litigations and other legal disputes, and other items that are deemed to be excluded based on the Company's judgment. A reconciliation table between results on a full basis and results on a core basis is provided on page 21 of the "Supplement Documents for Results 3Q/FY2015."

Impact of exchange rate on financial results

The exchange rates for the yen in the first nine months of FY2015 are shown in the table below. The resulting impacts were a ¥ 36.2 billion increase in sales and a ¥ 15.4 billion increase in core operating profit compared with if the exchange rates of the nine months of FY2014 were applied.

Average rate	First nine months of FY2014	**First nine months of FY2015**	Change
US$/¥	107	**122**	¥15 (Weakening of yen)
€/¥	140	**134**	¥6 (Strengthening of yen)

Change from beginning to end of period	As of December 31, 2014	**As of December 31, 2015**
US$/¥	¥18 (Weakening of yen)	**¥0 (Weakening of yen)**
€/¥	¥5 (Weakening of yen)	**¥1 (Weakening of yen)**

Sales

Consolidated sales in the first nine months of FY2015 increased by 11.8% compared to those in the corresponding period of the previous fiscal year ("year-on-year") to ¥1,065.7 billion.

- In addition to XTANDI for the treatment of prostate cancer, sales of overactive bladder (OAB) treatments Vesicare and Betanis / Myrbetriq / BETMIGA grew. Additionally, sales of products including Prograf, an immunosuppressant, increased.

Sales by region

*Sales by region calculated according to locations of sellers.

<Japan>

Sales in Japan increased by 2.1% year-on-year to ¥396.8 billion. Sales in the Japanese market increased by 2.9% year-on-year to ¥386.1 billion.

- There was growth in sales of XTANDI and other products, including overall sales of OAB treatments Vesicare and Betanis, Prograf, the anti-inflammatory and anti-pain drug Celecox, Symbicort for the treatment of bronchial asthma and Micardis for the treatment of hypertension.
- On the other hand, sales of products, including Lipitor for the treatment of hypercholesterolemia and Gaster for the treatment of peptic ulcer and gastritis declined, mainly due to the impact of generics.

<The Americas>

Sales in the Americas increased by 30.0% year-on-year to ¥348.7 billion. The sales on a U.S. dollar basis increased by 14.1% year-on-year to US$2,865 million.

- In addition to the sales of XTANDI, overall sales of OAB treatments VESIcare and Myrbetriq grew.
- Sales of the pharmacologic stress agent Lexiscan increased, and new products azole antifungal CRESEMBA contributed to increased sales.

<EMEA*>

Sales in EMEA increased by 3.3% year-on-year to ¥251.4 billion. The sales on a euro basis increased by 7.9% year-on-year to €1,871 million.

- In addition to XTANDI and overall OAB treatments Vesicare and BETMIGA, sales of Prograf and others grew.

* EMEA: Europe, Middle East and Africa.

<Asia and Oceania>

Sales in Asia and Oceania increased by 31.0% year-on-year to ¥68.8 billion.

- Products such as Prograf and Harnal for the treatment of functional symptoms of benign prostatic hyperplasia showed growth in sales.
- In addition, XTANDI and overall OAB treatments Vesicare and BETMIGA contributed to increased sales.

Core operating profit / Core profit for the period

- The increase in sales and a decrease in the cost-to-sales ratio resulted in a gross profit of ¥795.2 billion, up 14.7% year-on-year. The cost-to-sales ratio decreased 1.9 percentage points year-on-year to 25.4%, owing to changes in the product mix and other factors.
- Selling, general and administrative expenses increased by 14.3% year-on-year to ¥362.7 billion, which in addition to increased expenditures for co-promotion of XTANDI in the US, was partly due to the foreign exchange rate impact.
- Research and development (R&D) expenses were ¥165.0 billion, up 11.5% year-on-year, which, in addition to increased expenses related to progress of development projects, was partly due to the foreign exchange rate impact. The R&D cost-to-sales ratio was 15.5%.
- Amortisation of intangible assets was ¥33.2 billion, up 18.3% year-on-year.

As a result of the above, core operating profit increased by 16.8% year-on-year to ¥233.9 billion. Meanwhile, core profit for the period increased by 20.7% year-on-year to ¥169.4 billion and basic core earnings per share increased by 23.3% year-on-year to ¥78.16.

[Consolidated financial results (full basis)]

Consolidated financial results on a full basis in the first nine months of FY2015 are shown below. Sales, operating profit, profit before tax and profit for the period increased.

Items totaling of ¥19.4 billion, including impairment losses for property, plant and equipment, and net foreign exchange losses, which are excluded from results on a core basis, were recorded in "other expense." In addition, gain on sales of available-for-sale financial assets of ¥12.1 billion was recorded in "finance income." "Other expense" and gain on sales of available-for-sale financial assets in the same period of the previous fiscal year were ¥42.6 billion and ¥1.1 billion, respectively.

Consolidated financial results (full basis)

(Millions of yen)

	First nine months of FY2014	**First nine months of FY2015**	Change (%)
Sales	952,772	**1,065,666**	+112,894 (+11.8%)
Operating profit	161,680	**215,599**	+53,919 (+33.3%)
Profit before tax	161,617	**228,463**	+66,846 (+41.4%)
Profit for the period	114,744	**164,547**	+49,803 (+43.4%)
Basic earnings per share (yen)	51.87	**75.93**	+24.06 (+46.4%)
Comprehensive income	197,624	**166,544**	-31,080 (-15.7%)

(2) Information on financial position

1) Assets, equity and liabilities

An overview of the consolidated statement of financial position as of December 31, 2015 and the main changes from the end of the previous fiscal year are shown below.

Assets

Total assets as of December 31, 2015 saw a decrease of ¥5.8 billion compared to the end of the previous fiscal year to ¥1,787.8 billion.

<Non-current assets> ¥875.7 billion (an increase of ¥48.1 billion)

- Other intangible assets increased by ¥35.9 billion compared to the end of the previous fiscal year to ¥331.8 billion.

<Current assets> ¥912.1 billion (a decrease of ¥53.8 billion)

- Cash and cash equivalents decreased by ¥56.0 billion compared to the end of the previous fiscal year to ¥340.5 billion.

Equity

Total equity as of December 31, 2015 saw an increase of ¥4.4 billion compared to the end of the previous fiscal year to ¥1,322.3 billion, making the ratio of owners' equity to gross assets 74.0%.

- While profit for the period stood at ¥164.5 billion, the Company paid ¥69.6 billion of dividends of surplus and acquired ¥92.7 billion of its own shares.
- Cancellation of treasury shares totaling ¥49.6 billion (38 million shares) was carried out on May 29, 2015.

Liabilities

Total liabilities decreased by ¥10.2 billion compared to the end of the previous fiscal year to ¥465.5 billion.

<Non-current liabilities> ¥55.9 billion (an increase of ¥1.1 billion)
<Current liabilities> ¥409.6 billion (a decrease of ¥11.3 billion)

2) Cash flow

Cash flows from operating activities

Net cash flows from operating activities increased year-on-year by ¥20.1 billion to ¥174.7 billion.

- Income tax paid was ¥62.5 billion, an increase in outflow of ¥13.1 billion year-on-year.

Cash flows from investing activities

Net cash flows used in investing activities was ¥68.5 billion, an increase in outflow of ¥20.2 billion year-on-year.

- Purchases of property, plant and equipment used cash of ¥28.6 billion, and purchase of intangible assets used cash of ¥55.8 billion, while proceeds from sales of available-for-sale financial assets provided cash of ¥16.4 billion.

Cash flows from financing activities

Net cash flows used in financing activities was ¥163.1 billion, an increase in outflow of ¥70.4 billion year-on-year.

- Dividends paid totaled ¥69.6 billion, an increase in outflow of ¥7.5 billion year-on-year. Other outflow included cash of ¥92.7 billion used for the acquisition of own shares.

As a result of the above, cash and cash equivalents totaled ¥340.5 billion as of December 31, 2015, a decrease of ¥56.0 billion compared to the end of the previous fiscal year.

(3) Information on consolidated business forecasts for FY2015 and other forward-looking statements

The Company's business forecasts for FY2015 are presented on a core basis and full basis.
The consolidated full-year business forecasts for the fiscal year ending March 31, 2016 (FY2015) are shown below. The Company has chosen to leave its business forecasts unchanged from the consolidated full-year business forecasts announced in October 2015 because it does not expect large deviations from the forecasts.

Consolidated full-year business forecasts (core basis)

(Millions of yen)

	FY2014 Full-year results	**FY2015 Full-year forecasts**	Change (%)
Sales	1,247,259	**1,384,000**	+136,741 (+11.0%)
Core operating profit	216,500	**244,000**	+27,500 (+12.7%)
Core profit for the year	153,244	**175,000**	+21,756 (+14.2%)
Basic core earnings per share (yen)	69.37	**80.99**	+11.62 (+16.8%)

Consolidated full-year business forecasts (full basis)

(Millions of yen)

	FY2014 Full-year results	**FY2015 Full-year forecasts**	Change (%)
Sales	1,247,259	**1,384,000**	+136,741 (+11.0%)
Operating profit	185,663	**229,000**	+43,337 (+23.3%)
Profit before tax	189,683	**242,000**	+52,317 (+27.6%)
Profit for the year	135,856	**172,000**	+36,144 (+26.6%)
Basic earnings per share (yen)	61.50	**79.60**	+18.10 (+29.4%)

(Note1) The definition of financial results on a core basis is described in page 2.
(Note2) The forecasts for basic core earnings per share and basic earnings per share reflect acquisitions of own shares carried out from November 2 to December 1, 2015.

2. Matters Related to Summary Information (Notes)

(1) Changes in Accounting Policies and Accounting Estimates

The significant accounting policies adopted for the condensed interim consolidated financial statements of Astellas Pharma Inc. and its subsidiaries (collectively, the “Group”) for the nine months ended 31 December 2015 are the same as those applied for its consolidated financial statements for the fiscal year ended 31 March 2015, except for the new standard listed below.

The Group calculated income tax expense for the nine months ended 31 December 2015 based on the estimated average annual effective tax rate.

The following accounting standard is newly applied by the Group from the three months ended 30 June 2015. The standard does not have a material impact on the Group's condensed interim consolidated financial statements.

IFRS		Summary of new standard
IAS 19	Employee Benefits	Clarification of accounting for contributions by employees or third parties

3. Condensed Interim Consolidated Financial Statements
(1) Condensed Interim Consolidated Statements of Income

（Millions of Yen）

	Nine months ended 31 December 2014	Nine months ended 31 December 2015
Sales	952,772	1,065,666
Cost of sales	(259,478)	(270,492)
Gross profit	693,294	795,174
Selling, general and administrative expenses	(317,228)	(362,690)
Research and development expenses	(148,000)	(164,996)
Amortisation of intangible assets	(28,015)	(33,151)
Share of profits (losses) of associates and joint ventures	142	(475)
Other income	4,127	1,102
Other expense	(42,640)	(19,366)
Operating profit	161,680	215,599
Finance income	2,870	13,799
Finance expense	(2,933)	(936)
Profit before tax	161,617	228,463
Income tax expense	(46,873)	(63,916)
Profit for the period	114,744	164,547
Profit attributable to:		
Owners of the parent	114,744	164,547
Earnings per share		
Basic（Yen）	51.87	75.93
Diluted（Yen）	51.79	75.82

(2) Condensed Interim Consolidated Statements of Comprehensive Income

(Millions of Yen)

	Nine months ended 31 December 2014	Nine months ended 31 December 2015
Profit for the period	114,744	164,547
Other comprehensive income		
Items that will not be reclassified subsequently to profit or loss		
Remeasurements of defined benefit plans	(1,079)	2,497
Subtotal	(1,079)	2,497
Items that may be reclassified subsequently to profit or loss		
Foreign currency translation adjustments	77,945	590
Fair value movements on available-for-sale financial assets	6,015	(1,090)
Subtotal	83,959	(500)
Other comprehensive income, net of tax	82,880	1,997
Total comprehensive income	197,624	166,544
Total comprehensive income attributable to:		
Owners of the parent	197,624	166,544

(3) Condensed Interim Consolidated Statements of Financial Position

(Millions of Yen)

	As of 31 March 2015	As of 31 December 2015
Assets		
Non-current assets		
Property, plant and equipment	202,869	202,432
Goodwill	136,337	136,836
Other intangible assets	295,844	331,764
Trade and other receivables	15,588	22,285
Investments in associates and joint ventures	2,007	3,009
Deferred tax assets	51,199	58,673
Other financial assets	110,091	104,756
Other non-current assets	13,685	15,923
Total non-current assets	827,621	875,680
Current assets		
Inventories	156,907	148,637
Trade and other receivables	332,923	376,311
Income tax receivable	6,918	7,885
Other financial assets	59,908	21,749
Other current assets	12,732	16,887
Cash and cash equivalents	396,430	340,454
Sub total	965,819	911,922
Assets held for sale	139	200
Total current assets	965,958	912,122
Total assets	1,793,578	1,787,802

(Millions of Yen)

	As of 31 March 2015	As of 31 December 2015
Equity and liabilities		
Equity		
Share capital	103,001	103,001
Capital surplus	176,822	176,868
Treasury shares	(86,997)	(129,871)
Retained earnings	905,083	952,830
Other components of equity	220,007	219,466
Total equity attributable to owners of the parent	1,317,916	1,322,294
Total equity	1,317,916	1,322,294
Liabilities		
Non-current liabilities		
Trade and other payables	90	1,713
Deferred tax liabilities	38	—
Retirement benefit liabilities	30,059	29,301
Provisions	4,817	4,588
Other financial liabilities	626	761
Other non-current liabilities	19,142	19,505
Total non-current liabilities	54,771	55,868
Current liabilities		
Trade and other payables	226,602	199,145
Income tax payable	14,124	23,488
Provisions	85,423	96,296
Other financial liabilities	1,339	7,059
Other current liabilities	93,403	83,652
Total current liabilities	420,890	409,640
Total liabilities	475,662	465,508
Total equity and liabilities	1,793,578	1,787,802

(4) Condensed Interim Consolidated Statements of Changes in Equity

(Millions of Yen)

	Equity attributable to owners of the parent					
					Other components of equity	
	Share capital	Capital surplus	Treasury shares	Retained earnings	Subscription rights to shares	Foreign currency translation adjustments
As of 1 April 2014	103,001	176,822	(54,535)	864,830	2,110	147,660
Comprehensive income						
Profit for the period	—	—	—	114,744	—	—
Other comprehensive income	—	—	—	—	—	77,945
Total comprehensive income	—	—	—	114,744	—	77,945
Transactions with owners of the parent						
Acquisition of treasury shares	—	—	(30,012)	—	—	—
Disposals of treasury shares	—	—	270	(138)	(123)	—
Cancellation of treasury shares	—	—	25,398	(25,398)	—	—
Dividends	—	—	—	(62,146)	—	—
Share-based payments	—	—	—	—	234	—
Transfers	—	—	—	(1,079)	—	—
Total transactions with owners of the parent	—	—	(4,344)	(88,761)	111	—
As of 31 December 2014	103,001	176,822	(58,879)	890,813	2,221	225,605

As of 1 April 2015	103,001	176,822	(86,997)	905,083	2,241	177,306
Comprehensive income						
Profit for the period	—	—	—	164,547	—	—
Other comprehensive income	—	—	—	—	—	590
Total comprehensive income	—	—	—	164,547	—	590
Transactions with owners of the parent						
Acquisition of treasury shares	—	—	(92,671)	—	—	—
Disposals of treasury shares	—	—	219	(106)	(113)	—
Cancellation of treasury shares	—	—	49,577	(49,577)	—	—
Dividends	—	—	—	(69,615)	—	—
Share-based payments	—	46	—	—	73	—
Transfers	—	—	—	2,497	—	—
Total transactions with owners of the parent	—	46	(42,874)	(116,800)	(41)	—
As of 31 December 2015	103,001	176,868	(129,871)	952,830	2,200	177,895

(Millions of Yen)

	Equity attributable to owners of the parent				Total equity
	Other components of equity			Total	
	Fair value movements on available-for-sale financial assets	Remeasurements of defined benefit plans	Total		
As of 1 April 2014	28,588	—	178,359	1,268,476	1,268,476
Comprehensive income					
Profit for the period	—	—	—	114,744	114,744
Other comprehensive income	6,015	(1,079)	82,880	82,880	82,880
Total comprehensive income	6,015	(1,079)	82,880	197,624	197,624
Transactions with owners of the parent					
Acquisition of treasury shares	—	—	—	(30,012)	(30,012)
Disposals of treasury shares	—	—	(123)	8	8
Cancellation of treasury shares	—	—	—	—	—
Dividends	—	—	—	(62,146)	(62,146)
Share-based payments	—	—	234	234	234
Transfers	—	1,079	1,079	—	—
Total transactions with owners of the parent	—	1,079	1,190	(91,915)	(91,915)
As of 31 December 2014	34,603	—	262,429	1,374,186	1,374,186

As of 1 April 2015	40,461	—	220,007	1,317,916	1,317,916
Comprehensive income					
Profit for the period	—	—	—	164,547	164,547
Other comprehensive income	(1,090)	2,497	1,997	1,997	1,997
Total comprehensive income	(1,090)	2,497	1,997	166,544	166,544
Transactions with owners of the parent					
Acquisition of treasury shares	—	—	—	(92,671)	(92,671)
Disposals of treasury shares	—	—	(113)	0	0
Cancellation of treasury shares	—	—	—	—	—
Dividends	—	—	—	(69,615)	(69,615)
Share-based payments	—	—	73	119	119
Transfers	—	(2,497)	(2,497)	—	—
Total transactions with owners of the parent	—	(2,497)	(2,538)	(162,167)	(162,167)
As of 31 December 2015	39,371	—	219,466	1,322,294	1,322,294

(5) Condensed Interim Consolidated Statements of Cash Flows

(Millions of Yen)

	Nine months ended 31 December 2014	Nine months ended 31 December 2015
Cash flows from operating activities		
Profit before tax	161,617	228,463
Depreciation and amortisation	48,072	53,023
Impairment losses and reversal of impairment losses	9,145	9,309
Finance income and expense	63	(12,864)
(Increase) decrease in inventories	(6,043)	7,954
(Increase) decrease in trade and other receivables	(43,715)	(50,480)
Increase (decrease) in trade and other payables	6,310	(42,655)
Other	28,597	44,476
Cash generated from operations	204,047	237,227
Income tax paid	(49,485)	(62,546)
Net cash flows from operating activities	154,561	174,681
Cash flows from investing activities		
Purchases of property, plant and equipment	(12,420)	(28,630)
Proceeds from sales of property, plant and equipment	5,341	1,646
Purchase of intangible assets	(41,062)	(55,765)
Purchase of available-for-sale financial assets	(3,226)	(522)
Proceeds from sales of available-for-sale financial assets	4,084	16,450
Interest and dividends received	2,071	1,784
Other	(3,044)	(3,458)
Net cash flows used in investing activities	(48,257)	(68,495)
Cash flows from financing activities		
Acquisition of treasury shares	(30,012)	(92,671)
Dividends paid to owners of the parent	(62,146)	(69,615)
Other	(567)	(795)
Net cash flows used in financing activities	(92,724)	(163,081)
Effect of exchange rate changes on cash and cash equivalents	33,054	919
Net increase (decrease) in cash and cash equivalents	46,634	(55,976)
Cash and cash equivalents at the beginning of the year	391,374	396,430
Cash and cash equivalents at the end of the period	438,008	340,454

(6) Notes on going concern assumption

Not applicable.

Supplementary Documents [IFRS]

Financial results for the first nine months of the fiscal year 2015 (FY2015)

Astellas Pharma Inc.

- 3Q/FY2015 Financial Results
  - Nine months ended December 31, 2015
  - Three months ended December 31, 2015
- Pipeline list

<u>Cautionary statement regarding forward-looking information</u>

This material includes forward-looking statements based on assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties.

Actual financial results may differ materially depending on a number of factors including adverse economic conditions, currency exchange rate fluctuations, adverse legislative and regulatory developments, delays in new product launch, pricing and product initiatives of competitors, the inability of the company to market existing and new products effectively, interruptions in production, infringements of the company's intellectual property rights and the adverse outcome of material litigation.

This material contains information on pharmaceuticals (including compounds under development), but this information is not intended to make any representations or advertisements regarding the efficacy or effectiveness of these preparations, promote unapproved uses in any fashion nor provide medical advice of any kind.

[Nine months ended December 31, 2015]

1. Consolidated Results (Full Basis)

Unit: B¥

	FY14 APR. - DEC.	FY15 APR. - DEC.	Change	Change (%)	FY14 Full Year	Forecasts FY15 Full Year	Change from FY14 Change (%)
Sales	952.8	1,065.7	112.9	11.8%	1,247.3	1,384.0	11.0%
Cost of sales	259.5	270.5	11.0	4.2%	333.2		
Ratio to Sales	27.2%	25.4%			26.7%		
Gross profit	693.3	795.2	101.9	14.7%	914.1		
SG&A expenses	317.2	362.7	45.5	14.3%	452.5		
Ratio to Sales	33.3%	34.0%			36.3%		
Advertising and Sales Promotion	93.2	125.1	31.9	34.2%	138.5		
Personnel expenses	129.8	137.3	7.5	5.8%	178.1		
Other	94.3	100.4	6.1	6.4%	136.0		
R&D expenses	148.0	165.0	17.0	11.5%	206.6	238.0	15.2%
Ratio to Sales	15.5%	15.5%			16.6%	17.2%	
Amortisation of intangible assets	28.0	33.2	5.1	18.3%	38.7		
Share of profits/losses of associates and joint ventures	0.1	-0.5	-0.6	-	0.2		
Other income	4.1	1.1	-3.0	-73.3%	12.5		
Gain on sales of property, plant and equipment	1.4	0.3	-1.1	-76.5%	1.4		
Other expense	42.6	19.4	-23.3	-54.6%	43.3		
Loss on sales and disposal of property, plant and equipment	0.7	0.5	-0.2	-31.7%	1.2		
Impairment losses	9.1	9.5	0.4	4.1%	10.3		
Restructuring costs	11.5	-	-11.5	-	11.5		
Net foreign exchange losses	10.0	7.0	-3.0	-29.9%	3.6		
Litigation costs	11.0	2.1	-8.8	-80.5%	16.2		
Operating profit	161.7	215.6	53.9	33.3%	185.7	229.0	23.3%
Ratio to Sales	17.0%	20.2%			14.9%	16.5%	
Finance income	2.9	13.8	10.9	380.9%	7.1		
Gain on sales of available-for-sale financial assets	1.1	12.1	11.0	-	5.1		
Finance expense	2.9	0.9	-2.0	-68.1%	3.1		
Impairment losses for available-for-sale financial assets	2.6	0.1	-2.5	-95.0%	2.6		
Profit before tax	161.6	228.5	66.8	41.4%	189.7	242.0	27.6%
Ratio to Sales	17.0%	21.4%			15.2%	17.5%	
Income tax expense	46.9	63.9	17.0	36.4%	53.8		
Profit for the period	114.7	164.5	49.8	43.4%	135.9	172.0	26.6%
Ratio to Sales	12.0%	15.4%			10.9%	12.4%	
Comprehensive income	197.6	166.5	-31.1	-15.7%	169.5		

2. Consolidated Results (Core Basis)

Unit: B¥

	FY14 APR. - DEC.	FY15 APR. - DEC.	Change	Change (%)	FY14 Full Year	Forecasts FY15 Full Year	Change from FY14 (%)
Sales	952.8	1,065.7	112.9	11.8%	1,247.3	1,384.0	11.0%
Cost of sales	259.5	270.5	11.0	4.2%	333.2		
Ratio to Sales	27.2%	25.4%			26.7%		
Gross profit	693.3	795.2	101.9	14.7%	914.1		
SG&A expenses	317.2	362.7	45.5	14.3%	452.5		
Ratio to Sales	33.3%	34.0%			36.3%		
Advertising and Sales Promotion	93.2	125.1	31.9	34.2%	138.5		
Personnel expenses	129.8	137.3	7.5	5.8%	178.1		
Other	94.3	100.4	6.1	6.4%	136.0		
R&D expenses	148.0	165.0	17.0	11.5%	206.6	238.0	15.2%
Ratio to Sales	15.5%	15.5%			16.6%	17.2%	
Amortisation of intangible assets	28.0	33.2	5.1	18.3%	38.7		
Share of profits/losses of associates and joint ventures	0.1	-0.5	-0.6	-	0.2		
Operating profit	200.2	233.9	33.7	16.8%	216.5	244.0	12.7%
Ratio to Sales	21.0%	21.9%			17.4%	17.6%	
Finance income	1.8	1.7	-0.0	-1.7%	1.9		
Finance expense	0.3	0.6	0.3	92.8%	0.4		
Profit before Tax	201.7	235.1	33.4	16.5%	218.1		
Ratio to Sales	21.2%	22.1%			17.5%		
Income tax expense	61.4	65.7	4.3	7.0%	64.8		
Profit for the period	140.3	169.4	29.1	20.7%	153.2	175.0	14.2%
Ratio to Sales	14.7%	15.9%			12.3%	12.6%	

3. Exchange Rate

Unit: yen

	FY14 APR. - DEC.Ave.	FY15 APR. - DEC.Ave.	FY14 End	FY15 3Q End	FY14 Full Year	Forecasts FY15 Full Year
USD/Yen	107	122	120	121	110	121
EUR/Yen	140	134	130	132	139	133

∗ Exchange rate fluctuations had positive impact by 36.2 billion yen on sales and positive impact by 15.4 billion yen on Core operating profit in Q3/FY2015

4. Reconciliation of Full Basis to Core Basis

Unit: B¥

	FY14 APR. - DEC.			FY15 APR. - DEC.		
	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
Sales	**952.8**	**-**	**952.8**	**1,065.7**	**-**	**1,065.7**
Cost of sales	259.5	-	259.5	270.5	-	270.5
Gross profit	**693.3**	**-**	**693.3**	**795.2**	**-**	**795.2**
SG&A expenses	317.2	-	317.2	362.7	-	362.7
R&D expenses	148.0	-	148.0	165.0	-	165.0
Amortisation of intangible assets	28.0	-	28.0	33.2	-	33.2
Share of profits/losses of associates and joint ventures	0.1	-	0.1	-0.5	-	-0.5
Other income *1	4.1	-4.1	-	1.1	-1.1	-
Other expense *1	42.6	-42.6	-	19.4	-19.4	-
Operating profit	**161.7**	**38.5**	**200.2**	**215.6**	**18.3**	**233.9**
Finance income *2	2.9	-1.1	1.8	13.8	-12.1	1.7
Finance expense *2	2.9	-2.6	0.3	0.9	-0.4	0.6
Profit before tax	**161.6**	**40.1**	**201.7**	**228.5**	**6.6**	**235.1**
Income tax expense	46.9	14.5	61.4	63.9	1.8	65.7
Profit for the period	**114.7**	**25.5**	**140.3**	**164.5**	**4.8**	**169.4**

*1. “Other income” and “Other expense” are excluded from Core results.
“Other income” and “Other expense” include gain/loss on sale and disposal of property, plant and equipment, impairment losses, loss on the restructuring, litigation costs and foreign exchange gains/losses, etc.

*2. Gain/loss on sale of available-for-sale (“AFS”) and impairment losses of AFS included in “Finance income” and “Finance expense” are excluded from Core results as non-core items.

5. Segment Information by Region

Unit: B¥

		FY14 APR. - DEC.	FY15 APR. - DEC.	Change	Change (%)	FY14 Full Year	Forecasts FY15 Full Year	Change from FY14 (%)
Sales		952.8	1,065.7	112.9	11.8%	1,247.3	1,384.0	11.0%
	Japan	388.6	396.8	8.2	2.1%	498.7	504.4	1.2%
	Ratio to Sales	40.8%	37.2%			40.0%	36.4%	
	Americas	268.3	348.7	80.4	30.0%	361.0	452.1	25.2%
	Ratio to Sales	28.2%	32.7%			28.9%	32.7%	
	EMEA	243.3	251.4	8.1	3.3%	313.3	335.0	6.9%
	Ratio to Sales	25.5%	23.6%			25.1%	24.2%	
	Asia and Oceania	52.5	68.8	16.3	31.0%	74.2	92.5	24.6%
	Ratio to Sales	5.5%	6.5%			5.9%	6.7%	

- Calculated according to locations of sellers.
- EMEA: Europe, Middle East and Africa

6. Addition to Property, Plant and Equipment

Depreciation/Amortisation

Unit: B¥

		FY14 APR. - DEC.	FY15 APR. - DEC.	Change	Change (%)	FY14 Full Year	Forecasts FY15 Full Year	Change from FY14 (%)
Depreciation (PP&E)								
	Consolidated	16.0	15.5	-0.5	-3.1%	21.3	22.5	5.5%
Amortisation (Intangible Assets) *								
	Consolidated	32.1	37.6	5.4	17.0%	44.2	50.0	13.2%

* Amortisation (Intangible Assets): Including amortisation of software, etc.

7. Sales of major products

1) Sales of global products

Unit: B¥

	FY14 APR. - DEC.	FY15 APR. - DEC.	Change	Change (%)	FY14 Full Year	Forecasts FY15 Full Year	Change from FY14 Change (%)
XTANDI	94.9	188.8	93.8	98.8%	137.2	253.3	84.6%
US	59.4	112.9	53.5	90.1%	85.7	147.6	72.2%
ex-US	35.6	75.9	40.3	113.4%	51.5	105.8	105.3%
Japan	10.2	20.2	10.0	98.3%	14.9	28.0	88.4%
Americas (ex-US)	1.9	3.4	1.4	74.3%	2.6	4.3	65.2%
EMEA	23.1	50.7	27.5	118.9%	33.4	71.1	112.8%
Asia and Oceania	0.3	1.7	1.4	425.5%	0.6	2.3	280.8%
Eligard	14.6	13.7	-0.9	-6.3%	19.0	18.2	-4.3%
EMEA	14.6	13.5	-1.0	-7.1%	18.9	18.0	-5.1%
Asia and Oceania	0.0	0.2	0.1	370.6%	0.1	0.2	219.8%
Vesicare	104.2	104.8	0.7	0.6%	135.2	133.4	-1.3%
Japan	19.3	20.6	1.3	6.7%	25.6	27.0	5.5%
Americas	47.8	49.0	1.2	2.6%	61.4	62.4	1.5%
EMEA	32.9	30.9	-2.0	-6.0%	42.3	38.2	-9.7%
Asia and Oceania	3.8	4.0	0.3	7.4%	5.3	5.6	5.1%
Betanis/Myrbetriq/Betmiga	37.8	60.1	22.3	59.1%	53.1	81.9	54.0%
Japan	10.5	15.8	5.2	49.6%	14.8	22.1	49.2%
Americas	19.9	33.4	13.5	67.8%	27.9	44.3	59.0%
EMEA	7.2	10.1	2.9	40.4%	10.3	14.6	41.7%
Asia and Oceania	0.1	0.8	0.7	680.5%	0.2	0.9	420.0%
Harnal/Omnic	42.9	41.8	-1.1	-2.6%	56.0	56.0	0.0%
Sales by Astellas	40.2	39.3	-0.9	-2.2%	51.9	52.0	0.1%
Japan	11.8	10.1	-1.6	-13.9%	15.0	12.8	-14.4%
EMEA	14.8	12.3	-2.5	-17.0%	18.0	16.7	-7.0%
Asia and Oceania	13.2	16.3	3.1	23.8%	18.3	21.8	19.3%
Bulk and Royalties	2.7	2.5	-0.2	-8.5%	4.1	4.0	-2.0%
Prograf	147.8	157.5	9.7	6.5%	194.7	202.5	4.0%
Sales by Astellas	145.3	155.2	9.9	6.8%	190.9	199.8	4.7%
Japan (Including Graceptor)	37.3	39.0	1.8	4.7%	48.1	50.7	5.3%
Americas	25.6	26.9	1.3	5.2%	33.0	33.3	0.7%
EMEA	59.4	60.2	0.8	1.3%	77.7	77.3	-0.5%
Advagraf	21.7	23.9	2.2	10.0%	28.7		
Asia and Oceania	23.0	29.0	6.0	26.1%	32.0	38.5	20.6%
Exports to third parties	2.5	2.3	-0.2	-8.8%	3.8	2.7	-30.6%
Funguard/Mycamine	29.8	32.0	2.1	7.1%	38.8	42.4	9.3%
Japan	9.3	9.3	-0.1	-0.8%	11.8	12.1	3.0%
Americas	9.2	10.0	0.8	8.9%	12.4	12.9	4.7%
EMEA	8.2	8.5	0.3	3.2%	10.2	11.7	14.1%
Asia and Oceania	3.1	4.2	1.1	35.6%	4.4	5.6	28.2%
Protopic	18.0	12.1	-5.9	-32.9%	21.7	14.9	-31.2%
Americas	9.7	2.8	-6.8	-70.6%	10.3	2.9	-71.7%
EMEA	5.7	5.6	-0.1	-2.0%	7.8	7.0	-10.3%
Asia and Oceania	2.5	3.4	0.9	37.4%	3.4	4.8	39.6%

- Sales of products in Japan are shown in a gross sales basis.
- EMEA: Europe, Middle East and Africa

2) Sales of products in Japan

Unit: B¥

<Global products>	FY14 APR. - DEC.	FY15 APR. - DEC.	Change	Change (%)	FY14 Full Year	Forecasts FY15 Full Year	Change from FY14 Change (%)
XTANDI	10.2	20.2	10.0	98.3%	14.9	28.0	88.4%
Vesicare	19.3	20.6	1.3	6.7%	25.6	27.0	5.5%
Betanis	10.5	15.8	5.2	49.6%	14.8	22.1	49.2%
Harnal	11.8	10.1	-1.6	-13.9%	15.0	12.8	-14.4%
Prograf （Including Graceptor）	37.3	39.0	1.8	4.7%	48.1	50.7	5.3%
Funguard	9.3	9.3	-0.1	-0.8%	11.8	12.1	3.0%
<Local products in Japan>							
Micardis [Family]	75.1	76.9	1.8	2.5%	95.7	98.5	2.9%
Micombi	8.4	8.0	-0.4	-4.7%	10.7		
Micamlo	18.4	20.3	1.9	10.5%	23.8		
Celecox	31.6	36.2	4.5	14.3%	41.8	46.9	12.4%
Symbicort	25.0	28.9	3.9	15.5%	33.0	37.0	12.2%
Bonoteo	9.8	11.0	1.2	12.4%	13.0	14.5	11.5%
Geninax	8.1	8.6	0.5	5.6%	10.4	10.6	2.7%
Vaccines	33.5	38.6	5.1	15.2%	38.8	40.0	3.1%
Argamate	4.6	4.8	0.2	4.5%	5.9	6.2	3.6%
Kiklin	1.2	1.2	0.1	8.0%	1.5	1.7	12.1%
Gonax	2.6	3.0	0.4	14.8%	3.4	4.0	17.7%
Cimzia	3.8	5.0	1.2	32.2%	5.0	6.7	34.0%
Suglat	3.3	5.5	2.2	67.3%	4.1	8.3	102.6%
Lipitor*	29.0	24.8	-4.3	-14.8%	36.7	30.5	-17.0%
Myslee	15.1	14.2	-0.9	-5.8%	19.4	17.6	-9.1%
Gaster	14.2	11.8	-2.5	-17.3%	18.0	14.8	-17.8%
Seroquel	10.0	8.5	-1.5	-15.4%	12.6	10.7	-15.1%
Total Rx Sales In Japanese market	375.3	386.1	10.8	2.9%	481.7	489.8	1.7%

- Sales of products in Japan are shown in a gross sales basis.

*Transfer of Distribution for Caduet to Pfizer on April 1, 2015. Sales in FY2014 exclude sales of Caduet.

3) Sales of products in Americas and EMEA

Unit: B¥

		FY14 APR. - DEC.	FY15 APR. - DEC.	Change	Change (%)	FY14 Full Year	Forecasts FY15 Full Year	Change from FY14 Change (%)
Scan*	(Americas)	49.3	58.8	9.5	19.2%	66.3	77.8	17.3%
Lexiscan		49.1	58.6	9.5	19.4%	65.9		
AmBisome	(Americas)	6.6	8.2	1.7	25.7%	9.0	10.4	15.7%
Tarceva		37.0	37.3	0.3	0.9%	48.9		
	(US)	25.3	27.1	1.8	7.2%	33.5		
	(ex-US)	11.6	10.1	-1.5	-12.8%	15.3		
Qutenza	(EMEA)	1.4	1.6	0.2	12.9%	1.9		
DIFICLIR	(EMEA)	1.5	2.0	0.5	32.3%	2.0		

* Adenoscan + Lexiscan

- EMEA: Europe, Middle East and Africa

4) Sales in Americas and EMEA (Local currency)

Unit: M$

Americas	FY14 APR. - DEC.	FY15 APR. - DEC.	Change	Change (%)	FY14 Full Year	Forecasts FY15 Full Year	Change from FY14 Change (%)
Sales	2,511	2,865	355	14.1%	3,284	3,739	13.9%
XTANDI	573	955	382	66.5%	803	1,256	56.4%
US	555	927	372	67.0%	779	1,220	56.6%
Americas (ex-US)	18	28	10	53.1%	24	36	50.2%
Tarceva	346	306	-39	-11.4%	444		
US	237	223	-14	-5.9%	305		
ex-US	109	83	-26	-23.4%	139		
VESIcare	447	403	-44	-9.9%	559	516	-7.7%
Myrbetriq	186	275	88	47.4%	254	367	44.6%
Prograf	240	221	-18	-7.7%	301	275	-8.4%
Scan*	461	483	22	4.7%	603	643	6.7%
Lexiscan	459	482	22	4.9%	599		
MYCAMINE	86	82	-4	-4.4%	112	107	-4.8%
AmBisome	61	68	6	10.4%	82	86	5.2%
CRESEMBA	-	14	14	-	-		
Protopic	90	23	-67	-74.2%	94	24	-74.2%

* Adenoscan + Lexiscan

Unit: M€

EMEA	FY14 APR. - DEC.	FY15 APR. - DEC.	Change	Change (%)	FY14 Full Year	Forecasts FY15 Full Year	Change from FY14 Change (%)
Sales	1,734	1,871	137	7.9%	2,258	2,528	12.0%
XTANDI	165	377	212	128.6%	241	537	122.8%
Eligard	104	101	-3	-3.0%	136	136	-0.6%
Vesicare	234	230	-4	-1.8%	305	288	-5.4%
BETMIGA	51	75	24	46.6%	74	110	48.3%
Omnic	125	110	-15	-11.9%	159	157	-1.7%
Sales by Astellas	106	91	-14	-13.3%	130	126	-2.7%
Capsule	53	45	-8	-15.0%	63	64	0.8%
OCAS	53	46	-6	-11.7%	66	62	-6.0%
Bulk and Royalties	20	19	-1	-4.4%	30	30	2.6%
Prograf	442	465	24	5.4%	588	603	2.7%
Sales by Astellas	423	448	25	5.8%	560	583	4.1%
Advagraf	155	178	23	14.9%	207		
Exports to third parties	18	17	-1	-4.7%	28	20	-27.0%
MYCAMINE	58	63	5	7.7%	74	88	19.4%
Protopic	41	42	1	2.3%	56	53	-6.1%
Qutenza	10	12	2	17.9%	13		
DIFICLIR	11	15	4	38.1%	14		

- EMEA: Europe, Middle East and Africa

8.Consolidated statements of financial position

Unit: B¥

			31-Mar-15	31-Dec-15	
			Amount	Amount	Change
Assets			**1,793.6**	**1,787.8**	**-5.8**
	Non-current assets		**827.6**	**875.7**	**48.1**
		Property, plant and equipment	202.9	202.4	-0.4
		Goodwill	136.3	136.8	0.5
		Other intangible assets	295.8	331.8	35.9
		Trade and other receivables	15.6	22.3	6.7
		Investments in associates and joint ventures	2.0	3.0	1.0
		Deferred tax assets	51.2	58.7	7.5
		Other financial assets	110.1	104.8	-5.3
		Other non-current assets	13.7	15.9	2.2
	Current assets		**966.0**	**912.1**	**-53.8**
		Inventories	156.9	148.6	-8.3
		Trade and other receivables	332.9	376.3	43.4
		Income tax receivable	6.9	7.9	1.0
		Other financial assets	59.9	21.7	-38.2
		Other current assets	12.7	16.9	4.2
		Cash and cash equivalents	396.4	340.5	-56.0
		Assets held for sale	0.1	0.2	0.1

Unit: B¥

	31-Mar-15	31-Dec-15	
	Amount	Amount	Change
Equity and Liabilities	**1,793.6**	**1,787.8**	**-5.8**
Equity	**1,317.9**	**1,322.3**	**4.4**
Equity attributable to owners of the parent	**1,317.9**	**1,322.3**	**4.4**
Share capital	103.0	103.0	-
Capital surplus	176.8	176.9	0.0
Treasury shares	-87.0	-129.9	-42.9
Retained earnings	905.1	952.8	47.7
Other components of equity	220.0	219.5	-0.5
Liabilities	**475.7**	**465.5**	**-10.2**
Non-current liabilities	**54.8**	**55.9**	**1.1**
Trade and other payables	0.1	1.7	1.6
Deferred tax liabilities	0.0	-	-0.0
Retirement benefit liabilities	30.1	29.3	-0.8
Provisions	4.8	4.6	-0.2
Other financial liabilities	0.6	0.8	0.1
Other non-current liabilities	19.1	19.5	0.4
Current liabilities	**420.9**	**409.6**	**-11.3**
Trade and other payables	226.6	199.1	-27.5
Income tax payable	14.1	23.5	9.4
Provisions	85.4	96.3	10.9
Other financial liabilities	1.3	7.1	5.7
Other current liabilities	93.4	83.7	-9.8

[Three months ended December 31, 2015]

1. Consolidated Results (Full Basis)

Unit: B¥

	FY15					
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
Sales	343.7	16.4%	343.8	14.9%	378.2	5.5%
Cost of sales	90.1	18.6%	78.3	-5.8%	102.1	1.7%
Ratio to Sales	26.2%		22.8%		27.0%	
Gross profit	253.6	15.7%	265.5	22.8%	276.1	7.0%
SG&A expenses	118.7	22.4%	121.1	15.5%	122.9	6.5%
Ratio to Sales	34.5%		35.2%		32.5%	
Advertising and Sales Promotion	41.6	47.7%	41.7	55.3%	41.7	9.5%
Personnel expenses	45.1	6.3%	46.2	7.7%	46.0	3.4%
Other	32.0	21.4%	33.2	-5.5%	35.2	7.2%
R&D expenses	56.0	17.5%	56.1	13.5%	53.0	3.9%
Ratio to Sales	16.3%		16.3%		14.0%	
Amortisation of intangible assets	10.9	22.8%	11.0	21.5%	11.2	11.5%
Share of profits/losses of associates and joint ventures	-0.2	-	-0.0	-	-0.2	-
Other income	1.3	-53.2%	0.3	-91.0%	0.2	-78.7%
Gain on sales of property, plant and equipment	0.1	799.6%	0.1	-92.5%	0.1	567.0%
Net foreign exchange gains	0.6	-74.3%	-	-	-	-
Other expense	7.2	-60.4%	6.9	98.4%	5.9	-74.7%
Loss on sales and disposal of property, plant and equipment	0.1	-54.9%	0.2	-52.3%	0.2	35.5%
Impairment losses	6.6	-18.7%	-	-	3.0	264.6%
Restructuring costs	-	-	-	-	-	-
Net foreign exchange losses	-	-	6.5	794.3%	1.1	-90.8%
Litigation costs	0.4	-11.9%	0.1	709.5%	1.6	-84.5%
Operating profit	61.9	22.4%	70.7	34.4%	83.0	41.8%
Ratio to Sales	18.0%		20.6%		21.9%	
Finance income	6.0	230.4%	7.3	-	0.4	-25.1%
Gain on sales of available-for-sale financial assets	5.5	540.2%	6.6	-	-	-
Finance expense	0.3	-86.9%	0.3	-56.6%	0.4	149.6%
Impairment losses for available-for-sale financial assets	0.0	-98.5%	0.1	-87.8%	0.0	-
Profit before tax	67.7	34.6%	77.8	48.4%	83.0	40.9%
Ratio to Sales	19.7%		22.6%		22.0%	
Income tax expense	23.0	59.8%	19.4	6.4%	21.4	51.1%
Profit for the period	44.6	24.4%	58.3	70.9%	61.6	37.7%
Ratio to Sales	13.0%		17.0%		16.3%	
Comprehensive income	71.8	219.0%	33.0	-49.4%	61.7	-43.9%

2. Consolidated Results (Core Basis)

Unit: B¥

	FY15					
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
Sales	343.7	16.4%	343.8	14.9%	378.2	5.5%
Cost of sales	90.1	18.6%	78.3	-5.8%	102.1	1.7%
Ratio to Sales	26.2%		22.8%		27.0%	
Gross profit	253.6	15.7%	265.5	22.8%	276.1	7.0%
SG&A expenses	118.7	22.4%	121.1	15.5%	122.9	6.5%
Ratio to Sales	34.5%		35.2%		32.5%	
Advertising and Sales Promotion	41.6	47.7%	41.7	55.3%	41.7	9.5%
Personnel expenses	45.1	6.3%	46.2	7.7%	46.0	3.4%
Other	32.0	21.4%	33.2	-5.5%	35.2	7.2%
R&D expenses	56.0	17.5%	56.1	13.5%	53.0	3.9%
Ratio to Sales	16.3%		16.3%		14.0%	
Amortisation of intangible assets	10.9	22.8%	11.0	21.5%	11.2	11.5%
Share of profits/losses of associates and joint ventures	-0.2	-	-0.0	-	-0.2	-
Operating profit	67.8	2.8%	77.3	45.4%	88.7	9.5%
Ratio to Sales	19.7%		22.5%		23.5%	
Finance income	0.6	-43.2%	0.7	188.6%	0.5	-18.1%
Finance expense	0.1	-20.5%	0.2	257.6%	0.3	108.4%
Profit before Tax	68.3	2.2%	77.9	45.8%	88.9	9.1%
Ratio to Sales	19.9%		22.6%		23.5%	
Income tax expense	23.3	13.8%	19.0	1.1%	23.4	5.6%
Profit for the period	45.0	-3.0%	58.9	70.0%	65.4	10.5%
Ratio to Sales	13.1%		17.1%		17.3%	

3. Segment Information by Region

Unit: B¥

		FY15					
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
Sales		343.7	16.4%	343.8	14.9%	378.2	5.5%
	Japan	125.6	11.3%	121.5	-2.3%	149.7	-1.1%
	Ratio to Sales	36.6%		35.3%		39.6%	
	Americas	114.8	36.9%	118.1	40.3%	115.8	15.5%
	Ratio to Sales	33.4%		34.4%		30.6%	
	EMEA	81.7	-0.8%	80.5	8.7%	89.1	2.6%
	Ratio to Sales	23.8%		23.4%		23.6%	
	Asia and Oceania	21.5	34.0%	23.7	42.4%	23.6	18.9%
	Ratio to Sales	6.3%		6.9%		6.2%	

- Calculated according to locations of sellers.
- EMEA: Europe, Middle East and Africa

4. Depreciation/Amortisation

Unit: B¥

		FY15					
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
Depreciation (PP&E)							
	Consolidated	5.0	-4.5%	5.2	-6.2%	5.2	1.6%
Amortisation (Intangible Assets) *							
	Consolidated	12.4	21.1%	12.5	20.0%	12.7	10.5%

* Amortisation (Intangible Assets): Including amortisation of software, etc.

5. Sales of major products

1) Sales of global products

Unit: B¥

	FY15					
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
XTANDI	59.1	152.8%	63.3	102.4%	66.4	64.8%
US	36.2	146.7%	38.3	103.2%	38.4	48.5%
ex-US	22.8	163.2%	25.0	101.1%	28.0	94.0%
Japan	6.8	346.5%	6.3	53.3%	7.1	56.0%
Americas (ex-US)	1.0	151.6%	1.2	127.0%	1.1	13.7%
EMEA	14.6	117.3%	16.9	118.6%	19.1	120.5%
Asia and Oceania	0.4	-	0.6	937.5%	0.7	191.7%
Eligard	4.4	-12.3%	4.4	0.3%	4.8	-5.8%
EMEA	4.4	-12.9%	4.3	-0.9%	4.8	-6.7%
Asia and Oceania	0.0	349.7%	0.1	819.7%	0.1	231.7%
Vesicare	35.4	7.1%	34.3	2.3%	35.1	-6.6%
Japan	6.8	29.6%	6.5	-0.9%	7.2	-2.9%
Americas	17.1	9.9%	16.2	8.1%	15.7	-8.8%
EMEA	10.2	-7.2%	10.1	-2.7%	10.6	-7.9%
Asia and Oceania	1.2	7.6%	1.4	10.8%	1.4	4.1%
Betanis/Myrbetriq/BETMIGA	18.1	69.1%	20.0	71.7%	22.0	42.7%
Japan	4.9	81.0%	4.9	42.9%	6.0	35.8%
Americas	9.8	59.7%	11.6	93.2%	12.0	54.6%
EMEA	3.3	79.7%	3.3	52.7%	3.5	9.3%
Asia and Oceania	0.1	447.7%	0.2	396.9%	0.5	939.6%
Harnal/Omnic	14.2	3.4%	12.9	-5.6%	14.7	-5.2%
Sales by Astellas	13.3	6.2%	12.4	-5.2%	13.6	-6.6%
Japan	3.4	-11.6%	3.3	-17.1%	3.5	-12.9%
EMEA	4.7	3.7%	3.3	-27.6%	4.3	-25.0%
Asia and Oceania	5.0	25.5%	5.6	26.3%	5.7	20.2%
Bulk and Royalties	0.9	-25.4%	0.5	-13.1%	1.1	17.8%
Prograf	50.4	7.1%	54.2	12.6%	52.9	0.5%
Sales by Astellas	49.9	8.0%	53.2	12.6%	52.1	0.4%
Japan (Including Graceptor)	12.7	11.0%	12.7	3.7%	13.6	0.3%
Americas	8.4	-4.5%	9.7	19.4%	8.8	1.6%
EMEA	19.6	5.2%	20.5	4.0%	20.1	-4.6%
Advagraf	7.5	13.8%	8.3	12.9%	8.1	4.1%
Asia and Oceania	9.2	25.7%	10.3	43.7%	9.5	11.8%
Exports to third parties	0.5	-41.3%	1.0	13.1%	0.8	3.2%
Funguard/MYCAMINE	10.3	16.3%	10.8	12.0%	10.9	-4.3%
Japan	2.9	16.5%	3.1	-2.5%	3.2	-11.3%
Americas	3.3	15.5%	3.4	20.9%	3.3	-5.9%
EMEA	2.8	6.5%	2.8	14.0%	2.8	-8.2%
Asia and Oceania	1.3	49.2%	1.4	26.5%	1.5	34.4%
Protopic	4.2	-30.5%	3.7	-38.7%	4.2	-29.3%
Americas	1.0	-67.2%	0.9	-72.7%	0.9	-71.8%
EMEA	1.8	-13.4%	1.5	-17.0%	2.3	24.9%
Asia and Oceania	1.3	66.7%	1.3	46.1%	0.9	3.3%

- Sales of products in Japan are shown in a gross sales basis.
- EMEA: Europe, Middle East and Africa

2) Sales of products in Japan

Unit: B¥

	FY15					
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change
<Global products>	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
XTANDI	6.8	346.5%	6.3	53.3%	7.1	56.0%
Vesicare	6.8	29.6%	6.5	-0.9%	7.2	-2.9%
Betanis	4.9	81.0%	4.9	42.9%	6.0	35.8%
Harnal	3.4	-11.6%	3.3	-17.1%	3.5	-12.9%
Prograf （Including Graceptor）	12.7	11.0%	12.7	3.7%	13.6	0.3%
Funguard	2.9	16.5%	3.1	-2.5%	3.2	-11.3%
<Local products in Japan>						
Micardis [Family]	24.8	6.3%	23.7	-0.3%	28.4	1.5%
Micombi	2.7	-3.0%	2.5	-7.5%	2.9	-3.8%
Micamlo	6.5	14.5%	6.2	8.1%	7.6	9.3%
Celecox	11.8	41.4%	11.6	3.0%	12.7	6.1%
Symbicort	9.0	44.2%	8.5	3.5%	11.3	7.8%
Bonoteo	3.7	39.8%	3.4	-0.9%	3.9	5.3%
Geninax	2.8	20.9%	2.0	-2.5%	3.8	0.7%
Vaccines	6.6	24.6%	7.4	1.1%	24.6	17.8%
Argamate	1.5	6.5%	1.5	2.9%	1.7	4.1%
Kiklin	0.4	23.2%	0.4	3.0%	0.4	0.8%
Gonax	0.9	26.1%	1.0	11.6%	1.0	8.9%
Cimzia	1.6	40.1%	1.6	29.9%	1.8	27.9%
Suglat	2.0	-18.2%	1.4	-	2.0	187.3%
Lipitor*	8.3	-13.1%	7.9	-18.6%	8.5	-12.6%
Myslee	4.7	-3.6%	4.6	-8.5%	5.0	-5.1%
Gaster	3.9	-17.4%	3.8	-19.8%	4.0	-14.8%
Seroquel	3.0	-13.4%	2.7	-15.3%	2.8	-17.6%
Total Rx Sales In Japanese market	122.2	12.1%	117.8	-2.3%	146.1	0.3%

- Sales of products in Japan are shown in a gross sales basis.

*Transfer of Distribution for Caduet to Pfizer on April 1, 2015.

3) Sales of products in Americas and EMEA

Unit: B¥

	FY15					
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change
	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Scan* (Americas)	20.8	25.1%	19.8	27.1%	18.2	6.4%
Lexiscan	20.8	26.2%	19.7	26.4%	18.1	6.6%
AmBisome (Americas)	2.8	47.7%	2.7	19.5%	2.7	14.1%
Tarceva	13.1	-3.2%	12.4	11.1%	11.7	-3.9%
(US)	9.7	0.5%	8.9	17.4%	8.5	5.5%
(ex-US)	3.4	-12.3%	3.5	-2.4%	3.2	-22.2%
Qutenza (EMEA)	0.5	16.3%	0.5	15.6%	0.6	7.9%
DIFICLIR (EMEA)	0.6	34.7%	0.7	37.1%	0.6	25.5%

* Adenoscan + Lexiscan

- EMEA: Europe, Middle East and Africa

4) Sales in Americas and EMEA (Local currency)

Unit: M$

Americas	FY15 APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
Sales	946	15.2%	966	19.3%	953	8.3%
XTANDI	307	107.8%	323	73.1%	325	36.0%
US	298	107.6%	313	72.5%	316	37.2%
Americas (ex-US)	9	111.8%	10	92.7%	9	3.7%
Tarceva	108	-18.5%	101	-5.4%	97	-8.6%
US	80	-15.4%	73	0.0%	70	0.8%
ex-US	28	-26.1%	28	-16.9%	27	-26.7%
VESIcare	141	-7.5%	133	-8.0%	129	-14.1%
Myrbetriq	81	34.4%	95	64.4%	98	44.4%
Prograf	69	-19.6%	80	1.6%	73	-3.7%
Scan*	171	5.3%	162	8.1%	150	0.7%
Lexiscan	171	6.2%	161	7.5%	149	0.8%
MYCAMINE	27	-2.8%	28	2.8%	27	-12.0%
AmBisome	23	24.3%	22	1.4%	22	7.4%
CRESEMBA	2	-	5	-	7	-
Protopic	8	-72.4%	8	-76.8%	7	-73.1%

* Adenoscan + Lexiscan

Unit: M€

EMEA	FY15 APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
Sales	609	3.5%	592	10.0%	670	10.2%
XTANDI	109	126.9%	125	121.9%	144	136.1%
Eligard	33	-9.1%	32	0.3%	36	0.2%
Vesicare	76	-3.1%	75	-1.4%	80	-1.0%
BETMIGA	25	87.7%	25	54.9%	26	16.7%
Omnic	42	1.8%	28	-25.2%	40	-13.4%
Sales by Astellas	35	8.2%	24	-26.9%	32	-19.6%
Capsule	18	14.3%	11	-37.0%	16	-19.9%
OCAS	17	2.4%	14	-16.7%	16	-19.4%
Bulk and Royalties	7	-22.1%	4	-13.0%	8	26.5%
Prograf	150	7.6%	158	5.9%	157	2.8%
Sales by Astellas	146	9.8%	151	5.5%	151	2.5%
Advagraf	56	18.8%	61	14.6%	61	11.8%
Exports to third parties	4	-38.8%	7	15.0%	6	11.4%
MYCAMINE	21	11.2%	20	15.4%	21	-1.6%
Protopic	14	-9.5%	11	-16.2%	17	34.1%
Qutenza	4	21.5%	3	16.9%	4	15.6%
DIFICLIR	5	40.7%	5	39.0%	5	35.0%

- EMEA: Europe, Middle East and Africa

R&D Pipeline (As of January 2016)

Underlined items indicate for changes from the previous announcement on October 30, 2015.

1. Global Development

(1) Filed

*Compounds with "In-house" in this column include ones discovered by collaborative research. (The same applicable hereafter.)

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor*	Remarks
YM905 solifenacin	Muscarine M_3 receptor antagonist	Overactive bladder in pediatric patients of 5-18 years	Europe Filed (Sept. 2015)	Oral	In-house	New indication (pediatric)

(2) Phase-III / Phase-II (1/3)

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
MDV3100 enzalutamide	Androgen receptor inhibitor	Non-metastatic castration-resistant prostate cancer, Prostate cancer in patients with non-metastatic biochemical recurrence	US/Europe/Asia Phase-III	Oral	Medivation	New indication
		Metastatic hormone-sensitive prostate cancer	US/Europe/Japan/Asia Phase-III			New indication
		Breast cancer	US/Europe Phase-II			New indication
		Hepatocellular carcinoma	US/Europe/Asia Phase-II			New indication
ASP0113 (VCL-CB01)	DNA vaccine for cytomegalovirus	Cytomegalovirus reactivation in hematopoietic cell transplant recipients	US/Europe/Japan Phase-III	Injection	Vical	
		Cytomegalovirus infection or reactivation in solid organ transplant recipients	US/Europe Phase-II			

(2) Phase-III / Phase-II (2/3)

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
YM905 solifenacin	Muscarine M_3 receptor antagonist	Neurogenic detrusor overactivity in pediatric patients	US/Europe Phase-III	Oral	In-house	New indication (pediatric)
EB178 solifenacin/ mirabegron	Concomitant use of solifenacin and mirabegron	Urinary frequency, urinary incontinence or urgency associated with overactive bladder	US/Europe/Asia Phase-III	Oral	In-house	
fidaxomicin	Macrocyclic antibiotic	Infectious enteritis (bacterial target: *Clostridium difficile*)	Japan Phase-III	Oral	Merck	
		Clostridium difficile infection in pediatric patients	Europe Phase-III			New indication (pediatric)
ASP015K	JAK inhibitor	Rheumatoid arthritis	Japan/Asia Phase-III US/Europe Phase-II	Oral	In-house	
ASP1517 (FG-4592) roxadustat	HIF stabilizer	Anemia associated with chronic kidney disease in patients not on dialysis and on dialysis	Europe Phase-III Japan Phase-II	Oral	FibroGen	
ASP2215 gilteritinib	FLT3/AXL inhibitor	Acute myeloid leukemia	US/Europe/Japan/Asia Phase-III	Oral	In-house	
		Non-small cell lung cancer	US/Japan/Asia Phase-I			
ASP8273	Mutant-selective irreversible EGFR inhibitor	Non-small cell lung cancer	US/Europe/Japan/Asia Phase-III	Oral	In-house	
YM311 (FG-2216)	HIF stabilizer	Renal anemia	Europe Phase-II Japan Phase-I	Oral	FibroGen	

(2) Phase-III / Phase-II (3/3)

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
ASKP1240	Anti-CD40 monoclonal antibody	Prevention of organ transplant rejection	US Phase-II Japan Phase-I	Injection	Kyowa Hakko Kirin	
ASP1707	GnRH antagonist	Endometriosis	Europe/Japan Phase-II	Oral	In-house	
		Prostate cancer	Europe Phase-I			
ASP8232	VAP-1 inhibitor	Diabetic nephropathy	Europe Phase-II	Oral	In-house	
		Diabetic macular edema	US Phase-II			
ASP3662	11beta-HSD1 inhibitor	Painful diabetic peripheral neuropathy	US Phase-II	Oral	In-house	
		Alzheimer's disease	US Phase-I			
CK-2127107	Fast skeletal tropoinin activator	Spinal muscular atrophy	US Phase-II	Oral	Cytokinetics	
		Chronic obstructive pulmonary disease	US Phase-II			
ASP7962	TrkA inhibitior	Osteoarthritis	Europe Phase-II	Oral	In-house	
AGS-16C3F	ADC targeting ENPP3	Renal cell carcinoma (ADC technology)	US/Europe Phase-II	Injection	In-house (ADC technology in-licensed from Seattle Genetics)	

2. Local Development: Japan

(1) Approved

Code No. Generic Name	Product Name (Approval Date)	Classification	Target Disease	Area	Dosage Form	Licensor	Remarks
AMG 145 evolocumab (gene recombinant)	Repatha (Jan. 2016)	Anti-PCSK9 human monoclonal antibody	Treatment of patients with familial hypercholesterolemia or hypercholesterolemia who have high risk of cardiovascular events and are not adequately controlled by HMG-CoA reductase inhibitors	Japan	Injection	Amgen (co-development with Amgen Astellas)	

(2) Filed

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
ASP7374	Influenza vaccine	Prophylaxis of seasonal influenza	Japan Filed (May 2014)	Injection	UMN Pharma	
ASP1585 (AMG 223) bixalomer	Amine-functional polymer	Hyperphosphatemia in patients not on dialysis with chronic kidney disease	Japan Filed (Mar. 2015)	Oral	Amgen	New indication
		Hyperphosphatemia in patients on dialysis with chronic kidney disease (granule formulation)	Japan Filed (Sept. 2015)	Oral		New formulation

(3) Phase-III / Phase-II

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
FK949E quetiapine	Serotonin / dopamine antagonist	Depressive episode in bipolar disorders	Japan Phase-III	Oral	AstraZeneca	New indication New formulation
ASP3550 degarelix	GnRH antagonist	Prostate cancer (three-month formulation)	Japan Phase-III	Injection	Ferring	New formulation
AMG 785 romosozumab	Anti-Sclerostin monoclonal antibody	Osteoporosis	Japan Phase-III	Injection	Amgen (co-development with Amgen Astellas)	
ASP0456 linaclotide	Guanylate cyclase type-C receptor agonist	Irritable bowel syndrome with constipation	Japan Phase-III	Oral	Ironwood	
		Chronic constipation	Japan Phase-II			
ipragliflozin/ sitagliptin	Fixed dose combination of ipragliflozin and sitagliptin	Type 2 diabetes mellitus	Japan Phase-III	Oral	In-house (co-development with MSD and Kotobuki)	
ASP7373	Influenza vaccine	Prophylaxis of H5N1 influenza	Japan Phase-II	Injection	UMN Pharma	
ASP1941 ipragliflozin	SGLT2 inhibitor	Type 1 diabetes mellitus	Japan Phase-II	Oral	In-house (co-development with Kotobuki)	New indication

3. Phase-I

Code No. Generic Name	Target Disease	Dosage Form	Licensor
ASG-22ME	Cancer (ADC technology)	Injection	In-house (co-development with Seattle Genetics)
ASG-15ME	Cancer (ADC technology)	Injection	In-house (co-development with Seattle Genetics)
ASP5878	Cancer	Oral	In-house
YM178 mirabegron	Neurogenic detrusor overactivity and idiopathic overactive bladder in pediatric patients	Oral	In-house
AGS67E	Cancer (ADC technology)	Injection	In-house (ADC technology in-licensed from Seattle Genetics)
ASP2205	Stress urinary incontinence	Oral	In-house
ASP5094	Rheumatoid arthritis	Injection	In-house
ASP6858	Chronic kidney disease	Oral	In-house
AMG 103 blinatumomab	Acute lymphoblastic leukemia	Injection	Amgen (co-development with Amgen Astellas)
ASP4132	Cancer	Oral	In-house
ASP4345	Cognitive impairment associated with schizophrenia	Oral	In-house
ASP6282	Underactive bladder	Oral	In-house
ASP4070 (JRC2-LAMP-vax)	Pollinosis caused by Japanese red cedar	Injection	Immunomic Therapeutics
ASP0819	Fibromyalgia	Oral	In-house
ASP8062	Fibromyalgia	Oral	In-house
ASP7398	Nocturia	Oral	In-house
ASP6294	Bladder pain syndrome / Interstitial cystitis	Injection	In-house
ASP7266	Severe asthma	Injection	In-house

4. Project Discontinued

Code No. Generic Name	Target Disease	Area / Phase	Reason
isavuconazonium sulfate	Candidemia / Invasive candidiasis	US Phase-III	Decided not to continue the development in candidemia/invasive candidiasis, because the primary endpoint of the overall treatment response at the end of intravenous therapy was not met in the Phase-III study.

5. Other items changed from the previous quarterly announcement on October 30, 2015

-Removed the description of Qutenza (capsaicin patch), for which new indication was approved in Europe in August 2015.